, Jan. 23, 2014
/PRNewswire/ -- Royal DSM, the global Life Sciences and Materials Sciences Company, has won an appeal regarding the opposition of patent EP1232198, titled, UV Curable Compositions
at the European Patent Office Board of Appeal in Munich, Germany
on January 17, 2014
. This patent, currently assigned to 3D Systems, Inc., was revoked at the European level, thus allowing for increased development of materials in this field.
"We're pleased with the outcome as it encourages innovation in the area of photopolymers for stereolithography. We continue to focus on delivering the best materials to fit the industry and our customers' needs," says Melissa Hayes, Somos® Business Director for DSM.
DSM is committed to moving the industry to new levels of performance with their Somos® stereolithography materials, a distinct and unique subset of additive manufacturing. With over 20 years of industry experience, DSM offers a large portfolio of Somos® products that fit a wide range of applications and is dedicated to the success of this industry for the future.
DSM Bright Science. Brighter Living.
Somos® is a product brand of Royal DSM, a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials.
DSM's 23,500 employees deliver annual net sales of around 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com and www.dsm.com/somos
For more information:
DSM Functional Materials
Global Marketing Manager - Somos® Materials
Somos® is a trademark of DSM. Use of these trademarks is strictly prohibited unless authorized.
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained this press release, unless require by law.